Interfant 99 – treatment reflecting unique biology of the infant acute lymphoblastic leukemia. The results in the Czech Republic

Abstract

Five-years EFS of 482 patients enrolled in the international study Interfant 99 is 46% and overall survival 55% showing the improvement in comparison with majority of the previous studies.

Keywords

• acute lymphoblastic leukemia
• infants
• Interfant 99 study
• MLL rearrangement
• t(4
• 11) translocation